Compare NSP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | TSHA |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1996 | 2020 |
| Metric | NSP | TSHA |
|---|---|---|
| Price | $48.75 | $4.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $51.75 | $13.00 |
| AVG Volume (30 Days) | 434.2K | ★ 3.6M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $6,812,000,000.00 | $9,773,000.00 |
| Revenue This Year | $1.40 | N/A |
| Revenue Next Year | $4.27 | $1,023.00 |
| P/E Ratio | $49.85 | ★ N/A |
| Revenue Growth | 3.51 | ★ 17.28 |
| 52 Week Low | $18.57 | $3.69 |
| 52 Week High | $55.90 | $7.30 |
| Indicator | NSP | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 30.17 |
| Support Level | $47.12 | $4.37 |
| Resistance Level | $55.04 | $4.72 |
| Average True Range (ATR) | 1.93 | 0.23 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 60.42 | 14.20 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.